Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Unresectable Hepatocellular Carcinoma
NCT00047333Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2002
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 16 weeks. Started Aug 2002; status: terminated.
02
Drugs
erlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00047333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047333.